Thalidomide and Dacarbazine for Metastatic Melanoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to assess the activity of thalidomide in combination
with dacarbazine (DTIC) in patients with metastatic melanoma. Safety and toxicity of the two
drugs will also be assessed. Dacarbazine is the standard medical treatment for metastatic
melanoma. It has been shown to produce tumor shrinkage in approximately 20% of patients with
advanced melanoma. This shrinkage is usually incomplete and lasts a short time. Thalidomide
is a drug that inhibits tumor blood vessel growth. It can be given orally. It is hoped that
this combination can be given to patients with metastatic melanoma without causing too much
toxicity while increasing the response rate.